In this video, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, discusses challenges with developing immunotherapy in acute myeloid leukemia (AML), emphasizing the issue of shared antigens between AML cells and normal cells, which may lead to on-target, off-tumor toxicity. Prof. Konopleva also explains strategies which may be explored to overcome this challenge, including the use of antibody-drug conjugates (ADCs) and natural killer (NK) cells. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть